Jesteśmy aby ratować, leczyć, dawać nadzieję...
Wybierz język:

najważniejsze publikacje

  • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x.
  • Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction. Strojek K, Raz I, Jermendy G, Gitt AK, Liu R, Zhang Q, Jacober SJ, Milicevic Z. J Clin Endocrinol Metab. 2016 Jan;101(1):243-53. doi: 10.1210/jc.2015-1962. Epub 2015 Nov 23.
  • Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, Bhatt DL, Raz I. Diabetes Care. 2015 Nov;38(11):2142-50. doi: 10.2337/dc15-1068. Epub 2015 Sep 10.
  • Recommendations for health-enhancing physical activities in type 2 diabetes patients. Mynarski W, Cholewa J, Rozpara M, Borek Z, Strojek K, Nawrocka A. J Phys Ther Sci. 2015 Aug;27(8):2419-22. doi: 10.1589/jpts.27.2419. Epub 2015 Aug 21.
  • Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients? Strojek K, Górska J, Rokicka D, Szymborska-Kajanek A, Wróbel M, Sędek Ł, Szczepański T.;Endokrynol Pol. 2014;65(2):78-82. doi: 10.5603/EP.2014.0011.
  • Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M.; Pain. 2005 Jun;115(3):254-63. Epub 2005 Apr 18.
  • Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.; Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S.; Diabetes Ther. 2014 Jun;5(1):267-83. doi: 10.1007/s13300-014-0072-0. Epub 2014 Jun 12.
  • Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ.; Dia-betes Care. 2009 Mar;32(3):381-6. doi: 10.2337/dc08-1671.
  • Role of impaired glucose tolerance in patients with acute myocardial infarction in relation to sex. Sędkowska A, Kowalczyk J, Woźniak A, Kurek T, Zielińska T, Strojek K, Gumprecht J, Kalarus Z. Pol Arch Med Wewn. 2014;124(9):467-73. Epub 2014 Jul 4.
  • Discopathy of the lumbar-sacral segment and its influence on sexual dysfunction. Dzierżanowski M, Dzierżanowski M, Wrzecion K, Słomko W, Radzimińska A, Kaźmierczak U, Strojek K, Srokowski G, Żukow W.;Adv Clin Exp Med. 2013 Jan-Feb;22(1):93-100.
  • Features of macrovascular complications in type 2 diabetic patients.Strojek K.; Acta Diabetol. 2003 Dec;40 Suppl 2:S334-7.
  • Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? Strojek K, Grzeszczak W, Górska J, Leschinger MI, Ritz E. J Am Soc Nephrol. 2001 Mar;12(3):602-5.
  • Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients with diabetes or coronary artery disease in Poland: the Kardia-Pol registry. Opolski G, Strojek K, Kurzelewski M, Ostrowski M, Rabczenko D.;Pol Arch Med Wewn. 2012;122(9):413-21. Epub 2012 Jul 19.
  • Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Rob-bins DC; HEART2D Study.; J Diabetes Complications. 2005 Mar-Apr;19(2):80-7.
  • The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Barnett AH, Krentz AJ, Strojek K, Sieradzki J, Azizi F, Embong M, Imamoglu S, Perusicová J, Uliciansky V, Win-kler G.; Diabetes Obes Metab. 2008 Dec;10(12):1239-47. doi: 10.1111/j.1463-1326.2008.00894.x. Epub 2008 May 20.
  • Metformin - a new old drug.Wróbel MP, Marek B, Kajdaniuk D, Rokicka D, Szymborska-Kajanek A, Strojek K.; Endokry-nol Pol. 2017;68(4):482-496. doi: 10.5603/EP.2017.0050. Review.
  • Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Gasior M, Pres D, Stasik-Pres G, Lech P, Gierlotka M, Hawranek M, Wilczek K, Szyguła-Jurkiewicz B, Lekston A, Kalarus Z, Strojek K, Gumprecht J, Poloński L. Cardiol J. 2008;15(5):422-30.
  • Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction. Moejko-Pastewka B, Tatoń J, Haczyński J, Strojek K, Ametov AS, Milicevic Z. Acta Diabetol. 2003 Dec;40 Suppl 2:S354-7.
  • Expression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathy. Moczulski DK, Fojcik H, Wielgorecki A, Trautsolt W, Gawlik B, Kosiorz-Gorczynska S, Oczko-Wojciechowska M, Wiench M, Strojek K, Zukow-ska-Szczechowska E, Grzeszczak W. Diabet Med. 2007 Mar;24(3):266-71.
  • Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities.Khamaisi M, Wexler ID, Skrha J, Strojek K, Raz I, Milicevic Z.;Isr Med Assoc J. 2003 Nov;5(11):801-6.